series-a
Stage
2021
Founded
2
Investors
About
Trishula Therapeutics is a clinical-stage biotech company focused on developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers, aiming to improve treatment outcomes by targeting immune evasion mechanisms in tumors.
Explore Trishula Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.